Transforming healthcare through precision medicine.
Velsera’s vision is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help doctors and drug hunters make better decisions about providing the right therapy to the right patients at the right time. We have spent the last 10+ years’ developing industry leading clinical software, knowledge and perspectives on genetic disease - including oncology, rare and hereditary diseases.
Velsera was formed in January 2022 through the merger of three leading precision medicine companies – Perian Dx in the clinical diagnostics space, SevenBridges in the life science analytics domain and UgenTec in the clinical laboratory automation industry. Today, Velsera employs c.600 people across US, Europe and Asia, including over 150 employees with MD/PhD across our own in-house scientific, bioinformatic and clinical expert teams.
Our customer base includes some of the largest and most prestigious biopharma/biotech companies; government agencies and non-profits; clinical institutions and AMCs; diagnostic lab groups; we have partnerships with OEM lab instrument providers and also partner with diagnostic assay developers. The combination of our founding companies has created a unique capability and solution set to serve these customers across the diagnostic and drug development and commercialization life-cycle, including – (sub)population health, drug discovery, clinical development of new diagnostics and therapeutics, clinical delivery, lab management, RWD/E.
Driving perpetual innovation.
When knowledge flows freely between the clinical realm and R&D, a network effect arises: research discoveries translate to diagnostics, and patient outcomes inform new breakthroughs.
This virtuous cycle drives what we call the value loop—iterative learning and technology-enabled solutions that support all points in the healthcare continuum.
Our technology manages and orchestrates the flow of patient samples using cutting-edge tracking and tracing to guard the quality of data and maximize its use for research and diagnostics.
We apply AI and machine learning software to automate the analysis of multiple testing modalities, producing results that are qualitative, accurate and amenable for clinical annotation and reporting.
We equip clinicians with annotation that combines multi-omic data, clinical analytics and treatment guidelines to reveal relevant information for diagnosis, therapy options and response prediction.
Our teams curate a continuously growing knowledge base that effectively democratizes omics, providing unparalleled access to data and clinical information for accurate and up-to-date reporting.
We aggregate clinical information and its underlying raw data to provide a multi-omic view that enhances data from clinical trials and research studies, leveraging insight from both sides of the loop.
Our broad expertise integrating diverse datasets provides the tools and services needed to make data work together, unlocking unprecedented insights that make joint discovery possible.
Our data and knowledge bases can be accessed independently or in conjunction with Velsera experts, with AI and machine learning performing intelligent, deep analyses that yield actionable insights.
These data-driven insights drive precision R&D, improve drug discovery and clinical trials as well as inform routine diagnostics— closing the loop and setting the standard for omics-based healthcare.
Chief Executive Officer
Jamie joined Velsera in January 2024, having previously provided external support to Velsera and their founding business since early 2022. He has worked in healthcare and life sciences since 2010 and previously was a Partner at McKinsey & Company where he spent over a decade and led their Health & Life Science Investing Practice in Europe, specializing in supporting investor-backed health & life science tech businesses on their scale-up journeys.
Chief Product Officer
Nate has deep experience in product portfolio strategy, financial analysis and next-generation sequencing product development, as well as an extensive academic research background in molecular genetics and genomics. Prior to joining Velsera, he worked at Illumina for more than eight years.
Chief Administrative Officer
Purvesh has worked in executive level legal, strategy and business development roles at leading global technology and healthcare companies, including Calyx, Oracle and Syneos Health. He was most recently general counsel and chief compliance officer at Calyx before joining Velsera. Purvesh also serves as Velsera's chief legal officer and corporate secretary.
Chief Technology Officer
JP brings extensive experience in product development, software engineering and secure cloud hosting to Velsera. Most recently, he was the EVP of engineering at TalentReef, and beforehand he was the SVP of product development and cloud hosting services at Bioclinica.
Chief Operating Officer
Steven has strong operational experience in enterprise software organizations. Previously he was the CEO at UgenTec, where he developed the company into a global leader in molecular workflow automation. He also led informatics strategy and operations at Agilent Technologies and was COO at Cartagenia.
Working at Velsera.
Velsera offers a compelling, flexible work environment with a team of diverse mission-driven employees from around the globe. If you have an interest working for an organization with great values that is truly making a difference within science and healthcare, you have come to the right place!